Autonomix Medical, Inc. (AMIX)
| Market Cap | 4.00M -40.5% |
| Revenue (ttm) | n/a |
| Net Income | -16.11M |
| EPS | -36.37 |
| Shares Out | 1.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,584 |
| Open | 2.110 |
| Previous Close | 2.150 |
| Day's Range | 2.040 - 2.219 |
| 52-Week Range | 2.040 - 32.550 |
| Beta | -0.94 |
| Analysts | Buy |
| Price Target | 40.80 (+1,900.0%) |
| Est. Earnings | Nov 11, 2026 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company’s technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Med... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMIX stock is "Buy." The 12-month stock price target is $40.8, which is an increase of 1,900.00% from the latest price.
News
Autonomix announces CIPO issued patent for catheter-based tech
Autonomix (AMIX) Medical announced the Canadian Intellectual Property Office, CIPO, has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tis...
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Autonomix reports FDA feedback supporting 510k pathway to U.S. clearance
Autonomix (AMIX) Medical announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration, FDA, regarding the Company’s recently announced standalone transvas...
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standal...
Autonomix announces grant of European patent for neuromodulation platform
Autonomix (AMIX) Medical announced the grant of European Patent No. EP 4 233 700 B1, titled “Systems for Assessing Neural Activity in an Eye.” “This European patent represents another important…
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
Autonomix Medical Proxy statement: Proxy filing
Autonomix Medical filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
Autonomix Medical Proxy statement: Proxy filing
Autonomix Medical filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
Autonomix Medical Registration statement: Registration filing
Autonomix Medical filed a registration statement on September 4, 2026, providing details about a securities offering with the SEC.
Autonomix Medical Proxy statement: Proxy filing
Autonomix Medical filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Abstracts highlight potential of Autonomix's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (N...
Autonomix announces new U.S. patent
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office, or USPTO, titled “Systems and Methods for Regulating Organ and/or Tumor Growth…
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pa...
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix completes GLP preclinical study, plans FDA submission
Autonomix (AMIX) Medical announced the successful completion of its Good Laboratory Practice preclinical study, a significant regulatory milestone supporting the company’s submission to the FDA. The s...
Autonomix Medical Quarterly report: Q1 2027
Autonomix Medical has published its Q1 2027 quarterly earnings report on August 13, 2026.
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” o...
Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care
Autonomix Medical Inc trading resumes
09:41 EDT Autonomix (AMIX) Medical Inc trading resumes
Autonomix Medical Inc trading halted, volatility trading pause
09:31 EDT Autonomix (AMIX) Medical Inc trading halted, volatility trading pause
Why Is Penny Stock Autonomix Medical (AMIX) Up Today?
Autonomix Medical stock took off after the company revealed a new patent in the U.S.
Autonomix issued U.S. patent for nerve sensing, mapping
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands the company’s intellectual ...
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain
Autonomix files to sell 857,462 shares of common stock for holders
17:03 EDT Autonomix (AMIX) files to sell 857,462 shares of common stock for holders